Autoimmune Diseases  >>  fletikumab (NNC109-0012)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fletikumab (NNC109-0012) / Novo Nordisk
NCT01636817 / 2012-000609-58: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Terminated
2b
239
US, Europe, RoW
NNC0109-0012, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
11/14
11/14
NCT01636843 / 2012-000610-11: A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Terminated
2b
298
US, Europe, RoW
NNC0109-0012, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
11/14
11/14
NCT02097264 / 2013-001492-20: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Withdrawn
2a
0
Europe
NNC0109-0012, Adalimumab, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
09/15
09/15
NCT01282255 / 2010-021283-14: Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis

Checkmark P2a data - ISPOR 2012 (RA)
Nov 2012 - Nov 2012: P2a data - ISPOR 2012 (RA)
Checkmark P2 data - ACR/ARHP 2012 (RA)
Sep 2012 - Sep 2012: P2 data - ACR/ARHP 2012 (RA)
Checkmark Data - EULAR 2012
More
Completed
2
67
Europe
NNC109-0012, placebo
Novo Nordisk A/S
Inflammation, Rheumatoid Arthritis
01/12
01/12

Download Options